# OnCo record quizartinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/quizartinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "quizartinib" ;
  schema:name "Quizartinib"@en ;
  schema:description "Quizartinib is a more selective FLT3 blocker that, added to chemotherapy, roughly doubled median survival in the highest-risk FLT3 subtype."@en ;
  schema:url <https://onco.cc/drugs/quizartinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Quizartinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7272714> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Quizartinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (FLT3-ITD, type II)" ;
  schema:alternateName "Vanflyta" ;
  onco:approval "US 2023: Newly diagnosed FLT3-ITD AML with 7+3, consolidation, and maintenance", "Japan 2019: Relapsed/refractory FLT3-ITD AML" ;
  onco:related <https://onco.cc/biomarkers/flt3-itd/> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-flt3/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/flt3/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/> ;
  onco:trials <https://onco.cc/trials/quantum-first/>, <https://onco.cc/trials/nct06824168/>, <https://onco.cc/trials/nct03793478/> .